Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00635570 · ClinicalTrials.gov registry record · Phase 4
Acceptability of the NuvaRing Among Students
A Phase 4 study of Birth Control Compliance, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 4
- Development phase
- 273
- Enrollment target
- 3
- Study locations
NCT00635570 is a Phase 4 study of Birth Control Compliance that has completed, run by University of Chicago. The registered enrollment target is 273 participants. The trial reports 3 study locations across 1 state.
The verdict
NCT00635570, a Phase 4 study of Birth Control Compliance, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 273 participants
- Enrollment target
- 3
- Study locations
Study Summary
The ACCEPT study is a Phase IV trial in which women are randomized to either the NuvaRing® vaginal contraceptive ring or a low dose oral contraceptive to assess compliance, side effects, overall acceptability and intent to continue use of the method. The study is focused on the acceptability of the vaginal ring among female undergraduate or graduate students.
Conditions Studied
Interventions
- DRUG Ortho Tri-cyclen Lo
- DEVICE NuvaRing
Study Locations (3)
Illinois
- University of Chicago, Section of Family Planning - Chicago
- University of Chicago - Chicago
- University of Illinois - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 273 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00635570
The ClinicalTrials.gov registry entry for NCT00635570 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 273 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Birth Control Compliance appearing as the primary indexed condition, and to 2 interventions - of which Ortho Tri-cyclen Lo is the first listed.
NCT00635570 reports 3 study locations spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00635570 about?
NCT00635570 is a clinical study titled "Acceptability of the NuvaRing Among Students". The ACCEPT study is a Phase IV trial in which women are randomized to either the NuvaRing® vaginal contraceptive ring or a low dose oral contraceptive to assess compliance, side effects, overall acceptability and intent to continue use of the method. The study is focused on the acceptability of the ...
What is the current status of trial NCT00635570?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 273 participants. The study started on 2008-07. Estimated completion is 2009-07.
What conditions does trial NCT00635570 study?
This clinical trial studies the following conditions: Birth Control Compliance.
What interventions are being tested in trial NCT00635570?
The interventions under investigation include: Ortho Tri-cyclen Lo (DRUG), NuvaRing (DEVICE).
Who is sponsoring clinical trial NCT00635570?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00635570 being conducted?
This trial has 3 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.